← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

Publié par Yahoo Finance · États-Unis il y a 9 h

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi

The Motley Fool

Is It Too Late to Buy Energy Transfer After a 25% Rally? History Has a Clear Answer.

 MarketBeat

NORMA Group Unveils New Strategy Targeting 10%+ EBIT Margin by 2031

 MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

 Investing.com

Oppenheimer sees web, commerce software Q3 backdrop improving, AI worries linger

 Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

 Stocktwits

TeraWulf CEO Paul Prager Turns Elon Musk’s ‘Stranded Compute’ Warning Into A Buying Pitch